$KZR
Kezar Life Sciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024125457 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.706M
YoY Change -35.09%
% of Gross Profit
Research & Development $16.24M
YoY Change -31.58%
% of Gross Profit
Depreciation & Amortization $300.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $21.95M
YoY Change -32.52%
Operating Profit -$21.95M
YoY Change -14.02%
Interest Expense $403.0K
YoY Change 1.77%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.31M
YoY Change -12.06%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.31M
YoY Change -12.08%
Net Earnings / Revenue
Basic Earnings Per Share -$2.78
Diluted Earnings Per Share -$2.78
COMMON SHARES
Basic Shares Outstanding 7.296M 72.96M
Diluted Shares Outstanding 7.296M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.4M
YoY Change -31.99%
Cash & Equivalents $34.86M
Short-Term Investments $113.5M
Other Short-Term Assets $6.902M
YoY Change 638.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $156.4M
YoY Change -32.16%
LONG-TERM ASSETS
Property, Plant & Equipment $3.149M
YoY Change -28.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.415M
YoY Change -61.88%
Total Long-Term Assets $7.707M
YoY Change -59.03%
TOTAL ASSETS
Total Short-Term Assets $156.4M
Total Long-Term Assets $7.707M
Total Assets $164.1M
YoY Change -34.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.461M
YoY Change 10.93%
Accrued Expenses $9.664M
YoY Change -9.32%
Deferred Revenue
YoY Change
Short-Term Debt $3.913M
YoY Change
Long-Term Debt Due $3.913M
YoY Change
Total Short-Term Liabilities $20.43M
YoY Change 22.53%
LONG-TERM LIABILITIES
Long-Term Debt $6.349M
YoY Change -36.57%
Other Long-Term Liabilities $3.259M
YoY Change -51.36%
Total Long-Term Liabilities $6.349M
YoY Change -36.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.43M
Total Long-Term Liabilities $6.349M
Total Liabilities $30.04M
YoY Change -9.89%
SHAREHOLDERS EQUITY
Retained Earnings -$414.3M
YoY Change 30.08%
Common Stock $548.2M
YoY Change 2.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $134.0M
YoY Change
Total Liabilities & Shareholders Equity $164.1M
YoY Change -34.19%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$20.31M
YoY Change -12.08%
Depreciation, Depletion And Amortization $300.0K
YoY Change 0.0%
Cash From Operating Activities -$17.49M
YoY Change -13.44%
INVESTING ACTIVITIES
Capital Expenditures $18.00K
YoY Change -87.14%
Acquisitions
YoY Change
Other Investing Activities $24.08M
YoY Change 28.69%
Cash From Investing Activities $24.06M
YoY Change 29.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -17.49M
Cash From Investing Activities 24.06M
Cash From Financing Activities 0.000
Net Change In Cash 6.566M
YoY Change -512.96%
FREE CASH FLOW
Cash From Operating Activities -$17.49M
Capital Expenditures $18.00K
Free Cash Flow -$17.51M
YoY Change -13.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3434000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-225000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21658000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
169121000
CY2024Q2 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
56000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3085000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
150685000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3185000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
492000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-20313000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
134049000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
269872000
CY2023Q1 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
154000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4263000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
400000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22199000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
252490000
CY2023Q2 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
382000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4020000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-307000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24308000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
232277000
CY2023Q3 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
43000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6634000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
143000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23103000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
215994000
us-gaap Profit Loss
ProfitLoss
-63518000
us-gaap Profit Loss
ProfitLoss
-69610000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
781000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
786000
us-gaap Share Based Compensation
ShareBasedCompensation
9704000
us-gaap Share Based Compensation
ShareBasedCompensation
14917000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4128000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001645666
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38542
dei Entity Registrant Name
EntityRegistrantName
Kezar Life Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3366145
dei Entity Address Address Line1
EntityAddressAddressLine1
4000 Shoreline Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
822-5600
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7296222
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34858000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35493000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
113530000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165879000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7991000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
156379000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
206950000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3149000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3912000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2143000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4778000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2415000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5595000
CY2024Q3 us-gaap Assets
Assets
164086000
CY2023Q4 us-gaap Assets
Assets
221235000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3461000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8251000
CY2024Q3 kzr Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
9664000
CY2023Q4 kzr Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6481000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3391000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3012000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3913000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20429000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17744000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3259000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5852000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6349000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10069000
CY2024Q3 us-gaap Liabilities
Liabilities
30037000
CY2023Q4 us-gaap Liabilities
Liabilities
33665000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7296222
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7296222
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7277908
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7277908
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
548216000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
538456000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
107000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-130000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-414281000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350763000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
134049000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
187570000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164086000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221235000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7000000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16242000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23738000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49712000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63055000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5706000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8789000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17848000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20780000
CY2024Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1482000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
21948000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
32527000
us-gaap Operating Expenses
OperatingExpenses
69042000
us-gaap Operating Expenses
OperatingExpenses
83835000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21948000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25527000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69042000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76835000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2038000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2820000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6728000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8376000
CY2024Q3 us-gaap Interest Expense
InterestExpense
403000
CY2023Q3 us-gaap Interest Expense
InterestExpense
396000
us-gaap Interest Expense
InterestExpense
1204000
us-gaap Interest Expense
InterestExpense
1151000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-20313000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23103000
us-gaap Net Income Loss
NetIncomeLoss
-63518000
us-gaap Net Income Loss
NetIncomeLoss
-69610000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.78
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.78
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.6
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7296222
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7296222
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7268165
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7268165
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7286967
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7286967
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7249188
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7249188
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-20313000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23103000
us-gaap Net Income Loss
NetIncomeLoss
-63518000
us-gaap Net Income Loss
NetIncomeLoss
-69610000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
27000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-40000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
465000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
166000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
225000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
276000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
492000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
143000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
237000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
236000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19821000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22960000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63281000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69374000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
187570000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5298000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
193000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
176000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1549000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2413000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3850000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3180000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5661000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1607000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5388000
kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
1128000
kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
216000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57387000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62665000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1809000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
72102000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
130528000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
128804000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
180500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
56684000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48168000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
56000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
579000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
579000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-40000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-635000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13958000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35493000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40456000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34858000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26498000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
0
kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
4000
us-gaap Interest Paid Net
InterestPaidNet
1011000
us-gaap Interest Paid Net
InterestPaidNet
975000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-414300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its judgments, estimates and assumptions or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.</span></p>
CY2023 kzr Interest Rate Of Sublease Income Per Year
InterestRateOfSubleaseIncomePerYear
0.035
CY2023 kzr Discount Rate Of Cash Flow
DiscountRateOfCashFlow
0.133
CY2024Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
CY2024Q2 kzr Estimated Future Sublease Income
EstimatedFutureSubleaseIncome
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
959000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
76102000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
103000
CY2024Q3 kzr Debt Securities Avalilable For Sale Credit Related Losses
DebtSecuritiesAvalilableForSaleCreditRelatedLosses
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
147924000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
148265000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
147924000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
148265000
CY2024Q3 kzr Receivable From Collaboration
ReceivableFromCollaboration
500000
CY2023Q4 kzr Receivable From Collaboration
ReceivableFromCollaboration
1596000
CY2024Q3 kzr Prepaid Advance For Clinical Related Costs Current
PrepaidAdvanceForClinicalRelatedCostsCurrent
5268000
CY2023Q4 kzr Prepaid Advance For Clinical Related Costs Current
PrepaidAdvanceForClinicalRelatedCostsCurrent
1818000
CY2024Q3 kzr Prepaid License Dues And Subscription
PrepaidLicenseDuesAndSubscription
597000
CY2023Q4 kzr Prepaid License Dues And Subscription
PrepaidLicenseDuesAndSubscription
506000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
847000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
712000
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
589000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
695000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
190000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
251000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7991000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9350000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9332000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6201000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5420000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3149000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3912000
CY2024Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
800000
CY2023Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
800000
CY2024Q3 kzr Other Assets Advance For Clinical Related Costs Non Current
OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent
0
CY2023Q4 kzr Other Assets Advance For Clinical Related Costs Non Current
OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent
4787000
CY2024Q3 kzr Other Unbilled Receivable Non Current
OtherUnbilledReceivableNonCurrent
1741000
CY2023Q4 kzr Other Unbilled Receivable Non Current
OtherUnbilledReceivableNonCurrent
0
CY2024Q3 kzr Other Assets Deposits For Operating Lease
OtherAssetsDepositsForOperatingLease
674000
CY2023Q4 kzr Other Assets Deposits For Operating Lease
OtherAssetsDepositsForOperatingLease
674000
CY2024Q3 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
0
CY2023Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
134000
CY2024Q3 us-gaap Other Assets
OtherAssets
2415000
CY2023Q4 us-gaap Other Assets
OtherAssets
5595000
CY2024Q3 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
6070000
CY2023Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1801000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2120000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3708000
CY2024Q3 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1311000
CY2023Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
756000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
121000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
110000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
42000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9664000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2700000
CY2024Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
CY2024Q2 kzr Estimated Future Sublease Income
EstimatedFutureSubleaseIncome
0
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
762000
us-gaap Operating Lease Payments
OperatingLeasePayments
2215000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
457000
us-gaap Operating Lease Cost
OperatingLeaseCost
1778000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
466000
us-gaap Variable Lease Cost
VariableLeaseCost
1382000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3991000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3437000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7428000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
778000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6650000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3391000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3259000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6650000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
163000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
243000
CY2024Q3 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
425000
CY2023Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
312000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
10262000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10069000
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3913000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6349000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10069000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
10262000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10069000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5217000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4783000
CY2024Q3 kzr Long Term Debt Principal Amount
LongTermDebtPrincipalAmount
10000000
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P20Y
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
kzr Unvested Option Shares Cancelled Due To Termination
UnvestedOptionSharesCancelledDueToTermination
600000
CY2024Q3 kzr Share Based Compensation Expense Plan Modification Unamortized Incremental Compensation Cost Of Unvested Option Shares
ShareBasedCompensationExpensePlanModificationUnamortizedIncrementalCompensationCostOfUnvestedOptionShares
900000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1310651
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.95
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
118000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
578797
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
173821
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.43
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1715627
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
367000
CY2024Q3 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
884010
CY2024Q3 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
24.62
kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P5Y10M24D
CY2024Q3 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
3000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3185000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6634000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9704000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14917000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.862
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.873
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.876
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.862
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.879
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.876
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.883
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.041
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.046
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1400000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-20313000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-23103000
us-gaap Net Income Loss
NetIncomeLoss
-63518000
us-gaap Net Income Loss
NetIncomeLoss
-69610000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7296222
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7268165
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7286967
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7249188
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.78
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.78
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.6
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1726681
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1726681
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1363468
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1363468
CY2023 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
6200000
CY2024Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
30000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
1400000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023 us-gaap Restructuring Charges
RestructuringCharges
6187000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
1858000
CY2023 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
2908000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
1421000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
775000
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
646000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
1482000
CY2024Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
344000
CY2024Q2 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
1549000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
235000
CY2024Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
205000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
30000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 kzr Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 kzr Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0000950170-24-125457-index-headers.html Edgar Link pending
0000950170-24-125457-index.html Edgar Link pending
0000950170-24-125457.txt Edgar Link pending
0000950170-24-125457-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kzr-20240930.htm Edgar Link pending
kzr-20240930.xsd Edgar Link pending
kzr-ex31_1.htm Edgar Link pending
kzr-ex31_2.htm Edgar Link pending
kzr-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
kzr-20240930_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable